Physician profile
Deangelo Cooper
NPI 1528526704
$8,568.52
in general payments reported to CMS, 2019-2025
25 companies · $1,367 in 2025
The $1,367 reported for 2025 was more than what 86% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $922 · 2022: $2,124 · 2023: $2,295 · 2024: $1,860 · 2025: $1,367.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,325 · Education: $197.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,325.44 |
| Education | $196.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,346.03 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,246.25 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $1,137.56 | 2022-2025 | Uzedy, Austedo, Austedo Xr |
| Abbvie INC. | $927.70 | 2021-2025 | |
| Lundbeck LLC | $707.27 | 2021-2025 | Rexulti, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $540.34 | 2021-2025 | Spravato, Invega Trinza, Invega Sustenna |
| Alkermes, INC. | $503.29 | 2021-2023 | Aristada, Lybalvi |
| Takeda Pharmaceuticals U.S.A., INC. | $468.22 | 2021-2025 | Trintellix |
| Vanda Pharmaceuticals INC. | $340.54 | 2021-2025 | Fanapt |
| Axsome Therapeutics, INC. | $326.29 | 2022-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $312.46 | 2022-2025 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $198.02 | 2022-2023 | Qelbree |
| Almatica Pharma LLC | $99.85 | 2022-2023 | Sertraline Hcl, Loreev Xr |
| E.R. Squibb & Sons, L.L.C. | $64.37 | 2024 | Cobenfy |
| Merck Sharp & Dohme LLC | $61.22 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $45.24 | 2024 | Aplenzin, Wellbutrin |
| Idorsia Pharmaceuticals US INC | $45.11 | 2022-2023 | Quviviq |
| Eisai INC. | $42.40 | 2021 | |
| Tris Pharma INC | $35.47 | 2023-2024 | Dyanavel Xr |
| Avanir Pharmaceuticals, INC. | $28.81 | 2021-2022 | |
| Noven Therapeutics, LLC | $24.01 | 2024 | Xelstrym, Secuado |
| Acadia Pharmaceuticals INC | $20.49 | 2025 | Nuplazid |
| Boston Scientific Corporation | $16.53 | 2022 | |
| Neos Therapeutics, LP | $15.95 | 2023 | Adzenys Xr-Odt |
| Brainsway USA INC | $15.10 | 2025 | Deep Tms System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deangelo Cooper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.